Cargando…

Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer

OBJECTIVE: To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis. PATIENTS AND METHODS: A two cohort based evaluation for serum CGA for...

Descripción completa

Detalles Bibliográficos
Autores principales: Giridhar, Karthik V., Sanhueza, Cristobal, Hillman, David, Alkhateeb, Hassan, Carlson, Rachel, Tan, Winston, Costello, Brian A., Quevedo, Fernando, Pagliaro, Lance, Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126956/
https://www.ncbi.nlm.nih.gov/pubmed/29858590
http://dx.doi.org/10.1038/s41391-018-0046-9
_version_ 1783353393679433728
author Giridhar, Karthik V.
Sanhueza, Cristobal
Hillman, David
Alkhateeb, Hassan
Carlson, Rachel
Tan, Winston
Costello, Brian A.
Quevedo, Fernando
Pagliaro, Lance
Kohli, Manish
author_facet Giridhar, Karthik V.
Sanhueza, Cristobal
Hillman, David
Alkhateeb, Hassan
Carlson, Rachel
Tan, Winston
Costello, Brian A.
Quevedo, Fernando
Pagliaro, Lance
Kohli, Manish
author_sort Giridhar, Karthik V.
collection PubMed
description OBJECTIVE: To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis. PATIENTS AND METHODS: A two cohort based evaluation for serum CGA for prognostication in CRPC stage was performed using a screening cohort of 256 men with mCRPC and an independent validation cohort of 92 men with mCRPC. In both cohorts, men receiving proton pump inhibitors and those with non-castrate levels of testosterone (>50 ng/dl) were excluded. Serum CGA was measured in a homogeneous automated immunofluorescent assay using time-resolved amplified cryptate emission. In the validation cohort, CTC enumeration was also performed using the FDA cleared CELLSEARCH®CTC test. Cox proportional hazard regression models were used for prognostic association of serum CGA and CTC counts with overall survival. RESULTS: In the screening cohort 200 men were eligible for analysis. The median serum CGA was 100.3 ng/mL (interquartile range 67–161.3) and 34/200 were above the reference range. In the subset of men with Gleason scores ≥ 8, elevated CGA was associated with shorter overall survival [hazard ratio (HR) 2.19, p = 0.017]. In the validation cohort for 71 men eligible for analysis the median serum CGA was 90 ng/mL (interquartile range 55–156) and 31/71 patients had an elevated CGA. 51% of patients had a Gleason score ≥8 and 66/71 patients had CTCs enumerated with 26/66 with a CTC count ≥ 5 per 7.5ml blood sample (unfavorable). Both elevated serum CGA (HR 1.91, p = 0.043) and unfavorable CTC counts (HR 2.97, p = 0.0012) were adversely associated with overall survival and patients with ≥ 5 CTCs and elevated serum CGA had the shortest overall survival (HR 3.76, p = 0.008). CONCLUSION: Elevated serum CGA was negatively associated with OS in men with mCRPC. Serum CGA represents a prognostic biomarker that may complement CTC enumeration.
format Online
Article
Text
id pubmed-6126956
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-61269562018-12-01 Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer Giridhar, Karthik V. Sanhueza, Cristobal Hillman, David Alkhateeb, Hassan Carlson, Rachel Tan, Winston Costello, Brian A. Quevedo, Fernando Pagliaro, Lance Kohli, Manish Prostate Cancer Prostatic Dis Article OBJECTIVE: To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis. PATIENTS AND METHODS: A two cohort based evaluation for serum CGA for prognostication in CRPC stage was performed using a screening cohort of 256 men with mCRPC and an independent validation cohort of 92 men with mCRPC. In both cohorts, men receiving proton pump inhibitors and those with non-castrate levels of testosterone (>50 ng/dl) were excluded. Serum CGA was measured in a homogeneous automated immunofluorescent assay using time-resolved amplified cryptate emission. In the validation cohort, CTC enumeration was also performed using the FDA cleared CELLSEARCH®CTC test. Cox proportional hazard regression models were used for prognostic association of serum CGA and CTC counts with overall survival. RESULTS: In the screening cohort 200 men were eligible for analysis. The median serum CGA was 100.3 ng/mL (interquartile range 67–161.3) and 34/200 were above the reference range. In the subset of men with Gleason scores ≥ 8, elevated CGA was associated with shorter overall survival [hazard ratio (HR) 2.19, p = 0.017]. In the validation cohort for 71 men eligible for analysis the median serum CGA was 90 ng/mL (interquartile range 55–156) and 31/71 patients had an elevated CGA. 51% of patients had a Gleason score ≥8 and 66/71 patients had CTCs enumerated with 26/66 with a CTC count ≥ 5 per 7.5ml blood sample (unfavorable). Both elevated serum CGA (HR 1.91, p = 0.043) and unfavorable CTC counts (HR 2.97, p = 0.0012) were adversely associated with overall survival and patients with ≥ 5 CTCs and elevated serum CGA had the shortest overall survival (HR 3.76, p = 0.008). CONCLUSION: Elevated serum CGA was negatively associated with OS in men with mCRPC. Serum CGA represents a prognostic biomarker that may complement CTC enumeration. 2018-06-01 2018-09 /pmc/articles/PMC6126956/ /pubmed/29858590 http://dx.doi.org/10.1038/s41391-018-0046-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Giridhar, Karthik V.
Sanhueza, Cristobal
Hillman, David
Alkhateeb, Hassan
Carlson, Rachel
Tan, Winston
Costello, Brian A.
Quevedo, Fernando
Pagliaro, Lance
Kohli, Manish
Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title_full Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title_fullStr Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title_full_unstemmed Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title_short Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
title_sort serum chromogranin-a based prognosis in metastatic castration resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126956/
https://www.ncbi.nlm.nih.gov/pubmed/29858590
http://dx.doi.org/10.1038/s41391-018-0046-9
work_keys_str_mv AT giridharkarthikv serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT sanhuezacristobal serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT hillmandavid serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT alkhateebhassan serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT carlsonrachel serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT tanwinston serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT costellobriana serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT quevedofernando serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT pagliarolance serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer
AT kohlimanish serumchromograninabasedprognosisinmetastaticcastrationresistantprostatecancer